pmc.ncbi.nlm.nih.gov Open in urlscan Pro
2600:1901:0:c831::  Public Scan

Submitted URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118765/
Effective URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7118765/
Submission: On December 03 via api from US — Scanned from DE

Form analysis 4 forms found in the DOM

GET https://www.ncbi.nlm.nih.gov/search/all/

<form action="https://www.ncbi.nlm.nih.gov/search/all/" aria-describedby="search-field-desktop-navigation-help-text" autocomplete="off" class="usa-search usa-search--big ncbi-search-panel__form" data-testid="form" method="GET" role="search">
  <label class="usa-sr-only" data-testid="label" for="search-field-desktop-navigation"> Search… </label>
  <input class="usa-input" data-testid="textInput" id="search-field-desktop-navigation" name="term" placeholder="Search NCBI" type="search" value="">
  <button type="submit" class="usa-button
           

           
               
               
               
               
            

           
           
           
           " data-testid="button" data-ga-category="header" data-ga-action="NCBI" data-ga-label="header_search_button">
    <span class="usa-search__submit-text"> Search NCBI </span>
  </button>
</form>

<form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6" role="search">
  <label class="usa-sr-only" for="search-field"> Search </label>
  <input class="usa-input" id="search-field-mobile-navigation" type="search" placeholder="Search NCBI" name="search">
  <button type="submit" class="usa-button
           

           
               
               
               
               
            

           
           
           
           " data-ga-category="header" data-ga-action="NCBI" data-ga-label="header_search_button">
    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
    <img
      src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
      class="usa-search__submit-icon" alt="Search">
  </button>
</form>

<form class="usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form" autocomplete="off" role="search">
  <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
  <span class="autoComplete_wrapper flex-1">
    <input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search" type="search" name="term" data-autocomplete-url="/search/autocomplete/" aria-controls="autoComplete_list_1"
      aria-autocomplete="both" role="combobox" aria-owns="autoComplete_list_1" aria-haspopup="true" aria-expanded="false">
    <ul id="autoComplete_list_1" role="listbox" hidden="" aria-label="Suggestions"></ul>
  </span>
  <button class="usa-button" type="submit" formaction="https://www.ncbi.nlm.nih.gov/pmc/" data-ga-category="search" data-ga-action="PMC" data-ga-label="PMC_search_button">
    <span class="usa-search__submit-text">Search in PMC</span>
    <img src="/static/img/usa-icons-bg/search--white.svg" class="usa-search__submit-icon" alt="Search">
  </button>
</form>

<form id="collections-action-dialog-form" class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors" data-existing-collections-url="/list-existing-collections/"
  data-add-to-existing-collection-url="/add-to-existing-collection/" data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/" data-myncbi-max-collection-name-length="100"
  data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">
  <input type="hidden" name="csrfmiddlewaretoken" value="salBf4LhHQe1ZTVlDXNbGp7bCO7Dfj55rE3NG25nc5ITmnT8iA56NbMmvbQX2LG6">
  <fieldset class="usa-fieldset margin-bottom-2">
    <div class="usa-radio">
      <input type="radio" id="collections-action-dialog-new" class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0" name="collections" value="new" data-ga-category="collections_button" data-ga-action="click"
        data-ga-label="collections_radio_new">
      <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
    </div>
    <div class="usa-radio">
      <input type="radio" id="collections-action-dialog-existing" class="usa-radio__input usa-radio__input--tile collections-existing" name="collections" value="existing" checked="true" data-ga-category="collections_button" data-ga-action="click"
        data-ga-label="collections_radio_existing">
      <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
    </div>
  </fieldset>
  <fieldset class="usa-fieldset margin-bottom-2">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0"> Name your collection <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
      </label>
      <input type="text" name="add-to-new-collection" id="collections-action-dialog-add-to-new" class="usa-input collections-action-add-to-new" pattern="[^&quot;&amp;=<>/]*"
        title="The following characters are not allowed in the Name field: &quot;&amp;=<>/" maxlength="" data-ga-category="collections_button" data-ga-action="create_collection" data-ga-label="non_favorties_collection" required="">
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0"> Choose a collection </label>
      <select id="collections-action-dialog-add-to-existing" class="usa-select collections-action-add-to-existing" data-ga-category="collections_button" data-ga-action="select_collection"
        data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message"> Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </fieldset>
  <div class="display-inline-flex">
    <button class="usa-button margin-top-0 action-panel-submit" type="submit" data-loading-label="Adding..." data-pinger-ignore="" data-ga-category="collections_button" data-ga-action="click" data-ga-label="add"> Add </button>
    <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel" aria-label="Close 'Add to Collections' panel" ref="linksrc=close_collections_panel" data-ga-category="collections_button" data-ga-action="click"
      data-ga-label="cancel"> Cancel </button>
  </div>
</form>

Text Content

Skip to main content

An official website of the United States government

Here's how you know
Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United
States.

Secure .gov websites use HTTPS
A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to
the .gov website. Share sensitive information only on official, secure websites.


Search
Log in
 * Dashboard
 * Publications
 * Account settings
 * Log out

Search… Search NCBI

Primary site navigation

Search

Logged in as:

 * Dashboard
 * Publications
 * Account settings

Log in
Search PMC Full-Text Archive Search in PMC
 * Advanced Search
 * Journal List
 * User Guide

 * 
 * 
 * 
 * 
 * 


 * PERMALINK
   
   Copy

As a library, NLM provides access to scientific literature. Inclusion in an NLM
database does not imply endorsement of, or agreement with, the contents by NLM
or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice
Public Health
. 2014 Jan 1;128(2):141–147. doi: 10.1016/j.puhe.2013.08.008
 * Search in PMC
 * Search in PubMed
 * View in NLM Catalog
 * Add to search


THE WORLD HEALTH ORGANIZATION AND GLOBAL HEALTH GOVERNANCE: POST-1990

J Lidén


J LIDÉN

1Centre on Global Health Security, Chatham House, 10 St James's Square, London
SW1Y 4LE, United Kingdom
Find articles by J Lidén
1,∗
 * Author information
 * Article notes
 * Copyright and License information

1Centre on Global Health Security, Chatham House, 10 St James's Square, London
SW1Y 4LE, United Kingdom
∗

Tel.: +44 41792446006.

Received 2013 Apr 7; Revised 2013 Aug 9; Accepted 2013 Aug 9; Issue date 2014
Feb.

Copyright © 2013 The Royal Society for Public Health. Published by Elsevier Ltd.
All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free
information in English and Mandarin on the novel coronavirus COVID-19. The
COVID-19 resource centre is hosted on Elsevier Connect, the company's public
news and information website. Elsevier hereby grants permission to make all its
COVID-19-related research that is available on the COVID-19 resource centre -
including this research content - immediately available in PubMed Central and
other publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means with
acknowledgement of the original source. These permissions are granted for free
by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice
PMCID: PMC7118765  PMID: 24388640


ABSTRACT

This article takes a historical perspective on the changing position of WHO in
the global health architecture over the past two decades.

From the early 1990s a number of weaknesses within the structure and governance
of the World Health Organization were becoming apparent, as a rapidly changing
post Cold War world placed more complex demands on the international
organizations generally, but significantly so in the field of global health.

Towards the end of that decade and during the first half of the next, WHO
revitalized and played a crucial role in setting global health priorities.
However, over the past decade, the organization has to some extent been bypassed
for funding, and it lost some of its authority and its ability to set a global
health agenda. The reasons for this decline are complex and multifaceted. Some
of the main factors include WHO's inability to reform its core structure, the
growing influence of non-governmental actors, a lack of coherence in the
positions, priorities and funding decisions between the health ministries and
the ministries overseeing development assistance in several donor member states,
and the lack of strong leadership of the organization.

Keywords: History of global health, Global Health Governance, The World Health
Organization


INTRODUCTION

Since 1990, fundamental changes have been seen in both the wider political and
economic context that influences health outcomes and in the shape of the global
health architecture. To better understand these changes, this article attempts
to draw up a brief chronology of the period.

There are several ways of indicating changing levels of activity in global
health. For the purpose of this article the author have chosen to make use of
three: The amount of Official Development Assistance (ODA) going to global
health; the amount of innovation in terms of new
initiatives/partnerships/institutions created to engender activity in global
health; and global health outcomes.

It can be argued that these three indicators will emphasize the fight against
infectious diseases and other poverty-related health problems at the expense of
other vital functions of WHO, like non-communicable diseases, mental health, and
global health policies, standards and regulations. However, as funding and
health outcomes have become a central driver of global health priorities – and
therefore also in shaping the views of WHO's successes and weaknesses – it is
worth spending some time looking at the story these three indicators tell.

Since 1990, these three indicators all show roughly similar trends. Together,
they tell a story with three fairly distinct chapters: a period of relative
stagnation or even deterioration in health outcomes, with stagnation in
innovation and slow growth in funding from 1990 to 1997; a period of rapid
expansion of funding, increasing complexity in health architecture and improving
health outcomes from 1998 to 2009 and a period of uncertainty from 2010 onwards.

ODA and non-governmental funding for health increased by 49% from 1990 to 1997,
from US$5.74 billion to US$8.54 billion. Most of this increase came in bilateral
funding and in a significant increase in spending on health by the World Bank.
This rate of growth pales in comparison with the funding during the following
years. From 1998 to 2010, ODA and non-governmental funding for health grew 230%,
to US$28.2 billion.1

Similarly, the period from 1990 to 1997 saw only a handful of new initiatives
focused on global health. The period from 1998 to 2010, however, saw the birth
of several dozen partnerships, initiatives, foundations and institutions
dedicated to financing, coordinating or implementing global health programmes,
or achieve global health goals.2

The 1990s was dominated by the rapid spread and acceleration of the HIV/AIDS
pandemic from 8.9 million people living with HIV in 1990 to 23.1 million in
1997. AIDS deaths grew at a similarly rapid pace, from 380,000 in 1990 to 1.2
million seven years later.3 TB incidence grew slightly globally, but an alarming
growth in TB-HIV co-infection gave cause for concern and the rates of detection
and completed treatment were worryingly low. Figures for malaria – although
uncertain – indicated an increase in drug resistance, a growth in deaths and a
breakdown of control-efforts in many countries.4 Immunization rates of children
stagnated at just over 70% coverage during these years5 and efforts to introduce
additional vaccines to the routine immunizations largely failed.6 There was also
substantial concern during this period about the reduction in research and
development for new drugs and diagnostics for tropical diseases.7

These outcomes contrast with the positive results produced especially from 2004
onwards. Over the past ten years a reduction in new HIV infections and in AIDS
mortality, a sharp decline in TB deaths, a significant reduction in malaria
deaths, a steady increase in routine immunization coverage and the introduction
of several additional vaccines as well as the arrival and widespread uptake of
some important new drugs, vaccines and diagnostics for several diseases have
been seen.

The evolution of the World Health Organization is closely tied to these trends
and WHO has to a large extent been a driver of them. However, the author will
argue that the organization has also been aversely affected by the rapidly
changing landscape in global health, and that its influence and authority over
time have diminished, partly as a result of its own actions, but mainly as a
consequence of forces beyond its control.


THE 1990S: A DECADE OF BACKSLIDING IN GLOBAL HEALTH

In 1988, Dr Hiroshi Nakajima took over as Director General of the World Health
Organization as Dr Halfdan Mahler stepped down after 15 years in office.

During Nakajima's first five-year term, the post World War II order, which for
40 years had provided stability and predictability in world affairs, unravelled.
Some health consequences of the collapse of the Post War world order quickly
became apparent. The most visible was the dramatic increase in tuberculosis in
former Soviet states, as well as a deterioration of a wide range of health
indicators in countries facing political and economic turbulence following the
collapse of the Soviet Union.

WHO was largely unprepared for dealing with the health fallout of events that
were rooted in larger political and economic developments, in particular since
at the time it had a near exclusive interaction with nation states; states which
governments during the 1990s were often in continual transition and severely
weakened.

The rapid spread of the global HIV pandemic added to the pressures on WHO. Dr
Jonathan Mann, who had built up the General Program on AIDS within WHO from a
one-man operation when it started in 1986 to a $100 million program, resigned in
1990, citing ‘major disagreements’ with Nakajima.8 The creation of a UNAIDS
Secretariat independently of WHO in 1996 contributed to a sense that WHO was not
equipped to lead the fight against such a ‘modern’ disease with its need for a
complex, multifaceted response to issues like discrimination, judicial reform,
behavioural change, and prevention strategies that challenged cultural and
religious norms.9

Nakajima's focus was instead on using WHO for tasks that had brought successes
for Mahler. He hoped that WHO could repeat the achievement from the smallpox
eradication of the 1970s by creating a global campaign to eradicate polio.
Alarmed by the steep rise in TB cases, WHO from 1995 onwards also promoted the
adoption of the directly observed treatment short-course (DOTS), and in doing
so, initiated a wide-ranging reform of most countries' TB treatment. While
ultimately successful, these efforts only bore significant fruits in the
following decade, giving Nakajima little credit during his time in office.

Much attention has been paid to the controversies around Nakajima's person and
leadership – such as the conflict with Mann in 1990, a challenge to his
re-election in 1992 and the following accusations of bribery, and a call for his
resignation in 1995 following perceived racist remarks – but significant
structural weaknesses within WHO were threatening the effectiveness of the
institution independently of these scandals and they became increasingly
apparent during the 1990s. Nakajima's main mistake may have been to fail to
address these weaknesses head-on.10, 11

In late 1994, a series of articles in the British Medical Journal,12 listed the
main weaknesses in WHO's existing structure and work, only putting into focus
what had already been highlighted in several donor country and UN reports:13

 * 1.
   
   WHO's country work was of greatly varying quality and impact, and saw little
   regional strategy and coordination;

 * 2.
   
   its regional office structure fostered a lack of global coherence and
   coordination, added to bureaucracy, drove the politicization of health issues
   and promoted cronyism;

 * 3.
   
   its extra-budgetary programmes were driven by donor priorities rather than
   reflecting global health priorities, which led to internal competition for
   resources within WHO and weakened the organization's less tangible or outcome
   oriented work, such as its normative-, research- or monitoring activities;

 * 4.
   
   its inherent handicaps in addressing the increasingly complex social,
   economic and political determinants of health; and

 * 5.
   
   its inability to find constructive working arrangements with the increasing
   number of other institutions having a growing influence on global health
   policy or outcomes.

The decentralized structure was the result of a compromise at the creation of
WHO in 1948, stemming from the need to integrate the regional health
organizations that preceded WHO, and Nakajima had little power to change the
dynamics of this arrangement.

At the Headquarters in Geneva, he – as his successors – found it exceedingly
hard to unify and discipline his department and programme directors' competition
for extra-budgetary funding and – like his successors – found it difficult to
convince donor countries to provide untied funding.

In the 19 years since the BMJ series, these five areas have remained central to
the critique of WHO. Despite several attempts at reform during the past two
decades, WHO's organizational structure and its reliance on extra-budgetary
funding for donor-prioritized programmes remain largely unchanged. The criticism
today is strikingly similar to the one 19 years ago.14 In fact, the past two
decades have shown that it is exceedingly difficult for a Director General to
reform the structure of WHO, and while member states unite in their criticism of
the perceived weaknesses of the organization, they rarely agree on finding
solutions that can permanently alter the five areas of weakness outlined by
Godlee and many others over the years.


1998–2003: GROWTH AND COMPLEXITY

Dr Gro Harlem Brundtland, who was nominated as Director General to take over
from Nakajima in 1998, had campaigned on a platform of reform and the need to
set clear, strong priorities for global health.

Much faith was placed in Brundtland to revitalize WHO. She had several qualities
that set her apart from Nakajima and the other candidates she competed with for
the Director General position: She was an outsider and therefore not tied by
debts and loyalties to WHO staff and member states; as a long-time prime
minister of Norway and as the former head of the World Commission on Environment
and Development she enjoyed a standing and a respect which ensured that she was
listened to by presidents and prime ministers as well as health ministers; and
she was known as a pragmatist who would never let principle stand in the way of
a wanted outcome.

Brundtland's strategy to restore WHO's role as a leader in global health was to
set a clear agenda and define global priorities. She believed that once WHO's
thought-leadership was re-established, it would create a momentum that would
attract resources and place WHO at the head of the table in discussions with the
many new, emerging actors in the global health arena.15

From consultations with more than a dozen countries about their main health
concerns, she chose one priority among the infectious diseases – malaria – and
one among non-communicable diseases, tobacco control. However, her overarching
goal was to place health at the centre of the global discussions about
development. She knew that only if health was seen as a global political and
economic issue rather than a humanitarian and local concern, would presidents or
prime-, foreign- and finance ministers really get engaged.

She made no secret of this aim: it was stated in her first speech to the World
Health Assembly, May 1998,16 and repeated regularly in her speeches throughout
her time at WHO. Having already stated her political plan, she ‘reverse
engineered’ the process to provide scientific backing for it by setting up a
‘Commission on Macroeconomics and Health’ in 1999. Her plan was nicely aligned
with the ‘zeitgeist’ of her day; her vision fit very well with the work that
soon would lead to the creation of the Millennium Declaration with its eight
Millennium Development Goals (MDGs), and it positioned WHO to play a central
role in the initial work to achieve the MDGs.

Rather than creating a leadership from within the ranks of WHO, Brundtland
brought leading academic or policy figures in their fields to head what she
named as ‘clusters’ of activity within WHO. Many of these individuals commanded
much respect in the world of global health and immediately brought prestige to
the organization – at the cost, however, of some resentment and non-cooperation
among a few existing senior staff at WHO.

Brundtland quickly recognized that the implementation of a global health agenda
depended on large sums of additional resources and that these resources lay
outside the world of global health and also outside the remit of the health
ministries that made up the governance structures of WHO. She did not see WHO as
an implementing agency, but instead saw its role as providing direction,
leadership, coordination and technical expertise to those implementing a new,
ambitious health agenda. She therefore made WHO into a convener for partnerships
and initiatives to harness the growing political support for action in global
health.17

The first of these partnerships was Roll Back Malaria, which was initiated soon
after she took office. Subsequently, Brundtland worked to create or support new
initiatives where she felt there were gaps in the existing health architecture
(Medicines for Malaria Venture, GAVI, the Global TB Drug Facility, the Global
Fund), to bring parties together for dialogue where she felt there were
obstacles (pharmaceutical industry round-tables) and to organize partnerships
and alliances where she felt the many actors in a field needed direction and
coordination (Tobacco-Free Initiative, Partnerships for Health Sector
Development, Global Alliance To Eliminate Lymphatic Filariasis, Make Pregnancy
Safer, Stop TB Partnership, etc.).

While failing to raise the amount of mandatory budgetary contributions to WHO,
Brundtland oversaw a significant increase in voluntary, extra-budgetary
resources to the organization through her period in office. She formulated a
strategy to align such resources more closely with the organization's priorities
and needs.18

The Framework Convention on Tobacco Control, which was adopted by the World
Health Assembly in May 2003, was the first treaty negotiated under Article 19 of
WHO's Constitution. There were great expectations that the Convention heralded a
new era of global policies and treaties to assist countries in dealing with
supranational health issues. Indeed, Brundtland was forging ahead with what
promised to be a strong global policy on nutrition, but after her departure, the
final policy fell victim to industry pressure and was weakened to a point where
it has become only a shadow of the strong instrument Brundtland envisaged to
help countries' efforts to control obesity, high blood pressure and other
nutrition-related health issues.

During the last months of her first and only term, a global outbreak of a so far
unknown virus – quickly termed SARS (Severe Acute Respiratory Syndrome) – tested
WHO's ability to lead a global response to disease outbreaks. Brundtland's
forceful response and insistence on immediate and accurate sharing of
transmission data by all countries reaffirmed WHO as the global authority and
coordinator in such global emergencies and forced through a faster and more
accurate reporting system than in the past.19

There is a general consensus, therefore, that Brundtland was successful in
re-establishing WHO's leadership in setting a global health agenda, in setting
global priorities and in coordinating global efforts. She managed to confront
complex health-related issues where both causes and solutions lay outside the
medical field by engaging WHO in the political determinants, such as in the
tobacco control issue and in getting acceptance for the close link between
health and economic development.

However, she made little headway in improving the quality and uniformity of
WHO's work in countries and was not able to bring the regional directors behind
her efforts to reform the organization. She also faced persistent resistance
among some WHO staff to Headquarters reforms and to some of the senior deputies
she had brought in.20

Personal health issues21 prevented Brundtland from seeking a second five-year
term in office, and it is therefore impossible to say to what extent her
internal reform efforts failed or whether they simply were not completed by the
time she stepped down in July 2003.


2003–2012: WHO'S DIMINISHING ROLE IN GLOBAL HEALTH

The Global Health landscape changed considerably between 1998 and 2003. Health
had become a central theme on the international agenda – in particular for the
G8. Funding increased, but this funding was largely channelled outside WHO. The
U.S. President's Emergency Plan for AIDS Relief (PEPFAR) not only dwarfed all
other sources of funding for any health intervention except the Global Fund, but
it also engaged technical expertise other than WHO in countries. Universities
like Harvard and Johns Hopkins, NGOs like Partners in Health, Catholic Relief
Services and World Vision, and a raft of consultants, were financed through
PEPFAR to provide strategic advice, technical support and also to large extent
to implement large disease programmes in several development countries.

The Global Fund's grant model, which encouraged countries to procure technical
assistance and to engage NGOs as Principal and Sub Recipients for its grants,
contributed to this boom in non-WHO technical and operational engagement in
developing countries. Not only did WHO in many countries lose out in the
‘competition’ with NGOs and academic institutions for fast, relevant and
high-quality advice; many countries were also reluctant to pay WHO for advice
that they had come to expect for free by WHO Country Offices.

WHO (and to a lesser extent UNAIDS) thus increasingly voiced its concern that by
being enlisted as a technical partner to the Global Fund, the Fund had imposed
an ‘unfunded mandate’ on the organization.22

Moreover, the Bill and Melinda Gates Foundation became the single largest
non-governmental funder of health research in infectious and vaccine-preventable
diseases (as well as a major funder of GAVI, the Global Fund and a raft of
health advocacy initiatives and partnerships), and over time, its money and its
growing self confidence and expertise in health matters made it a strong – if
informal – authority in setting global health priorities and influencing
policies.

Jong Wok Lee, who took over as Director General in 2003, reversed some of
Brundtland's reforms (re-introducing the pre-Brundtland leadership structure
with Assistant Director Generals, re-centralized some decision-making processes)
and de-emphasized some of Brundtland's priorities (in particular an ambitious
and aggressive push to improve global nutrition), while he emulated some
practices, such as bringing outside authorities in certain fields into the
senior leadership (in particular Jim Yong Kim, who was brought in to lead an
ambitious push for expansion of AIDS treatment, the ‘Three by Five Initiative’).

Lee was, like Nakajima, someone who had a long career at WHO before he took the
helm of the organization. He was by personality a consensus builder, focusing on
technical aspects of global health rather than the political leadership style of
Brundtland. He was somewhat hampered by having been elected with a weak mandate
(an election stalemate had only been broken to secure him a 17/15 vote after
three tied rounds of voting in the Executive Board).23

Lee campaigned on providing additional resources to WHO country offices, but
wanted to achieve this through increased overall funding rather than a large
reallocation of funds from the Geneva Headquarters. This put significant
fund-raising pressures on WHO and some concerns were voiced that it increased
the ‘cherry-picking’ nature of donor priorities, diffusing a unified global
agenda.

Lee's major focus would be on the ‘Three by Five Initiative’, and while it did
not reach its goal of ensuring that three million people were receiving AIDS
treatment by the end of 2005 (the three million mark was achieved in 2007), it
has been credited with energizing the global effort to provide access to AIDS
treatment and to the goal of achieving universal access to such treatment.

However, the ‘Three by Five Initiative’ illustrated the challenges WHO faced by
operating in a much more crowded and complex global health environment. While
WHO strengthened the technical capacity in Geneva, it struggled to do the same
at a sufficient scale in the country offices. WHO, which had over the past year
yielded the position of adviser to governments to UNAIDS, struggled to draw up
the separation of responsibilities between the two organizations, leading to
confusion in many countries.

The Global Fund was designed to make funding decisions based on country
applications and WHO therefore found that the organization was ill-equipped to
adjust funding priorities based on requests and priorities from WHO's
Headquarters. PEPFAR even less so. Moreover, Bill Gates was for several years
sceptical to the entire argument that providing universal treatment access was a
cost-efficient intervention. In short, with so much new money available for
global health programmes outside WHO's sphere of influence, its voice became
less one of unquestioned authority but increasingly only one of several
opinions.

This tension has continued to evolve over the past years. UNITAID, which was
created in 2006, although it is hosted by WHO, makes funding decision through
its multistakeholder Board. The many issue-specific partnerships that have grown
up – in particular Roll Back Malaria and Stop TB Partnership – provide advocacy
and even technical advice independently of WHO, and are not always fully aligned
with WHO's respective departments.

NGOs and activist organizations now wield a considerably larger influence than
in the past, partly through their effective advocacy and partly by being
admitted as formal stakeholders on the Global Fund, GAVI, UNITAID, UNAIDS and
partnership boards.

Even WHO's leading position in providing health metrics has been challenged by
the creation of the Seattle-based and partly Gates funded Institute for Health
Metrics and Evaluation, set up by Christopher Murray after he left WHO shortly
after Brundtland's term ended.

The SARS epidemic in 2003 re-established WHO as a global authority and
coordinator on disease outbreaks, and Margaret Chan, who was elected Director
General after Lee's untimely death in 2006, re-emphasized this role. Chan, who
had led Hong Kong's health department through the 1997 avian influenza epidemic
and the SARS episode in 2003, was expected to further strengthen WHO's role in
this field. However, WHO's widely criticized reaction to the avian influenza
outbreak in 2009 weakened the organization's authority also in this area.24

While there have been some successes in getting international agreements on
global health issues, WHO Director-Generals subsequent to Brundtland did not
attempt bold global efforts similar to the Tobacco Convention or global policies
or standards on controversial issues. However, a renewed version of the
International Health Regulations was crafted after the scare provided by the
SARS outbreak in 2003 and was approved in 2005.

Some significant initiatives have been undertaken over the past decade to
somehow address important challenges in global health. The most noteworthy of
these may be the Commission on Social Determinants of Health, the Global Code of
Practice on the International Recruitment of Health Personnel and the work
leading up to a UN General Assembly Special Session on non-communicable diseases
in 2011. Most recently, WHO has promoted a goal of ‘Universal Health Coverage’
and has lobbied hard to make this the primary health goal of what will
eventually become a ‘Post 2015 Agenda’ to replace the soon expired Millennium
Development Goals.

For all the good work that has gone into these initiatives, there is a strong
feeling expressed in various forms and forums25 that WHO's actions are ad-hoc
and derivative, that the initiatives are disparate, lack strategic direction and
follow-up. In short, WHO, according to these critics, has lost its way and is
simply staggering around in the dark, devoid of ideas and clarity of purpose.

While extra-budgetary funding for WHO continued to increase significantly during
the years following Brundtland's departure (voluntary contributions increased
from US$1.5 billion in the 2002–2003 biennium to US$3.6 billion in the 2010–2011
biennium), concern has been raised that there has not been a proportional
‘return’ on this donor investment in terms of WHO technical assistance,
agenda-setting and leadership.25

The rise of global health institutions outside the UN system and an increasing
influence of non-governmental actors, such as foundations and activists, have
often been used to explain WHO's relative decline.

However, from the standpoint of the WHO HQ leadership, the often disparate and
sometimes conflicting priorities within WHO member countries themselves, is
perceived to pose a major challenge to the organization's ability to reform and
to get support and funding for a clear future direction.26 There is a perceived
disconnect between the priorities of health ministries, which govern WHO through
its Executive Board and the World Health Assembly on the one hand, and
Ministries of Foreign Affairs and Departments of Development Assistance, which
provide the bulk of financing for global health through overseas development
assistance, on the other.

This latter funding is not only channelled through bilateral aid initiatives,
such as PEPFAR; they finance the plethora of new institutions and initiatives
that now to a large extent drive the global health agenda. They also, crucially
for WHO, provide the bulk of the extra-budgetary funding for the organization.27

WHO may therefore fall victim to countries which may have one set of priorities
expressed in WHO's own governing forums, while their funding to WHO and other
institutions may reflect a different set of priorities.

Too little is known, however, about the correlation or possible disconnect
between individual countries' voting record and recorded positions on strategic
issues in the Executive Board and the World Health Assembly and their funding
record for WHO's extra-budgetary activities to draw any conclusions about the
validity of such concerns at this stage.

Over the past few years, stagnating contributions combined with an acute
financial crisis at WHO Headquarters in Geneva triggered by the strong Swiss
franc, forced significant staff lay-offs and led to renewed demands for drastic
reforms of the organization.

Over the past two years, the WHO leadership has struggled to align its governing
organs' priorities with its funding realities. Yet, for its wide scope and
considerable detail, the reform efforts do little in terms of prioritizing the
use of the organization's limited resources and focusing on its comparative
strengths.20

Nor does it address the key structural weaknesses identified back in the early
1990s, in particular the regional structure and the varying quality of country
offices. While discussions at this year's World Health Assembly focused on WHO's
interaction with non-state actors, the discussion did not find a formula for how
WHO can best function in a by now considerably more crowded and complex health
architecture, where non-governmental organizations play a significant role.

WHO and its defenders describe the organization's current weak state as a
reflection of its Members States' diverse and sometime contradictory needs,
opinions and demands. However, for outside observers, the ongoing, overly
technical reform effort more than anything masks the fact that WHO over the past
decade has lacked a decisive leadership and visionary ideas to set a clear
direction for the global health agenda and to lead the world towards it.


CONCLUSION

The growing number of actors with political or economic power over the past
fifteen years, the lack of coherence in the positions and priorities between
health and development ministries within member states, the unresolved
weaknesses of WHO's regional structure, and the lack of a visionary leader of
the organization, together pose significant challenges for WHO as it is seeking
to reform itself to a global environment very different from 20 years ago.


AUTHOR STATEMENTS


ETHICAL APPROVAL

None sought.


FUNDING

None declared.


COMPETING INTERESTS

None declared.


REFERENCES

 * 1.Institute for Health Metrics and Evaluation . 2012. Financing global health
   in 2012: the end of the Golden Age? Seattle, WA. [Google Scholar]
 * 2.Lidén J. Chatham House; 2013. The grand decade for global health,
   1998–2008. [Google Scholar]
 * 3.UNAIDS . 2012. Global report: UNAIDS report on the global AIDS epidemic.
   Geneva. [Google Scholar]
 * 4.The World Bank . 1999. Roll back malaria FY 99 status report. Washington
   D.C. [Google Scholar]
 * 5.WHO/UNICEF . July 2011. Coverage estimates 2010, revision. [Google Scholar]
 * 6.Muraskin W. 1998. The politics of international health: the children's
   vaccine initiative and the struggle to develop vaccines for the third world.
   New York. [Google Scholar]
 * 7.Trouiller P. Recherche et développement pharmaceutiques en matière de
   maladies transmissibles dans la zone intertropicale. Santé. 1996;6:299–307.
   [PubMed] [Google Scholar]; Pecoul B., Chirac P., Trouiller P., Pinel J.
   Access to essential drugs in poor countries: a lost battle? J Am Med Assoc.
   January 27, 1999;281(4) doi: 10.1001/jama.281.4.361. [DOI] [PubMed] [Google
   Scholar]
 * 8.New York times. March 17, 1990. [Google Scholar]
 * 9.Merson M.H. The HIV–AIDS pandemic at 25 – the global response. N Engl J
   Med. 2006;354(23) doi: 10.1056/NEJMp068074. [DOI] [PubMed] [Google Scholar]
 * 10.Peabody J. An organizational analysis of the World Health Organization:
   narrowing the gap between promise and performance. Soc Sci Med.
   1995;40:731–742. doi: 10.1016/0277-9536(94)00300-i. [DOI] [PubMed] [Google
   Scholar]
 * 11.Reddy S. 50 years of the World Health Organization: looking back and
   moving forward. Natl Med J India. 1998 May–Jun;11(3):107–109. [PubMed]
   [Google Scholar]
 * 12.Godlee F. The World Health Organization: WHO in crisis. BMJ.
   1994;309:1424. doi: 10.1136/bmj.309.6966.1424. [DOI] [PMC free article]
   [PubMed] [Google Scholar]; Godlee F. WHO in retreat: is it losing its
   influence? BMJ. 1994;309:1491. doi: 10.1136/bmj.309.6967.1491. [DOI] [PMC
   free article] [PubMed] [Google Scholar]; Godlee F. The World Health
   Organization: the regions – too much power, too little effect. BMJ.
   1994;309:1566. doi: 10.1136/bmj.309.6968.1566. [DOI] [PMC free article]
   [PubMed] [Google Scholar]; Godlee F. The World Health Organization: WHO at
   country level – a little impact, no strategy. BMJ. 1994;309:1636. doi:
   10.1136/bmj.309.6969.1636. [DOI] [PMC free article] [PubMed] [Google
   Scholar]; Godlee F. The World Health Organization: WHO's special programmes:
   undermining from above. BMJ. 1995;310:178–182. doi:
   10.1136/bmj.310.6973.178a. [DOI] [PMC free article] [PubMed] [Google Scholar]
 * 13.Edgren G., Moller B. The United Nations: issues and options, Nordic UN
   Project Stockholm. 1991. The agencies at a crossroads: the role of United
   Nations specialized agencies. Cowiconsult, Effectiveness of Multilateral
   Agencies at Country Level, DANIDA, 1991; UN Joint Inspection Unit:
   Decentralization of Organizations within the United Nations System. Part III:
   The World Health Organization, Geneva, 1993, discussed in: Clift, C: The Role
   of the World Health Organization in the International System Working Paper,
   Chatham House 2013. [Google Scholar]
 * 14.Chow J. Is the WHO becoming irrelevant? Foreign Policy. 8 December, 2010
   [Google Scholar]; Legge D. Future of WHO hangs in the balance. BMJ.
   2012;345:e6877. doi: 10.1136/bmj.e6877. [DOI] [PubMed] [Google Scholar]
 * 15.The description of Dr Brundtland’s intentions and philosophy is based on
   numerous conversations between the author and Dr Brundtland and her key
   advisers.
 * 16.Brundtland G.H. 13 May 1998. Speech to the fifty-first world health
   assembly. Geneva. [PubMed] [Google Scholar]
 * 17.WHO: Executive Board EB107/7; 2000.
 * 18.WHO: Executive Board EB104/3 1999.
 * 19.Heymann D. SARS legacy: outbreak reporting is expected and respected.
   Lancet. 2013;381:779–781. doi: 10.1016/S0140-6736(13)60185-3. [DOI] [PMC free
   article] [PubMed] [Google Scholar]
 * 20.Clift C. Chatham House; 2013. The role of the World Health Organization in
   the international system working paper. [Google Scholar]
 * 21.Much speculation has been done on the motives for Dr Brundtland’s
   unexpected decision to step down after only one term. Dr Brundtland has in
   later years revealed to former colleagues that two specific and potential
   life-threatening health conditions convinced her that it would be
   irresponsible to continue with the work load and travel schedule the Director
   General position demanded.
 * 22.Global Task Team on improving AIDS coordination among multilateral
   institutions and international donors: final report. June 2005. p. 17.
   [Google Scholar]; The Global Fund to fight AIDS, tuberculosis and malaria:
   report of The Global Fund Board Retreat on Partnerships. 2008. GF/B18/15.
   [Google Scholar]
 * 23.Avery D. WHO; 2012. Lee Jong-Wook: a life in health and politics. [Google
   Scholar]
 * 24.Council of Europe . 2010. The handling of the H1N1 pandemic: more
   transparency needed. Doc 12283. [Google Scholar]; Doshi P. The elusive
   definition of pandemic influenza. Bull World Health Organ. 2011;89:532–538.
   doi: 10.2471/BLT.11.086173. [DOI] [PMC free article] [PubMed] [Google
   Scholar]
 * 25.Bloom B. WHO needs change. Nature. 2011;473 doi: 10.1038/473143a. [DOI]
   [PubMed] [Google Scholar]; Legge D. Furture of WHO hangs in the balance. BMJ.
   2012;345:e6877. doi: 10.1136/bmj.e6877. [DOI] [PubMed] [Google Scholar]; Chow
   J. Is WHO becoming irrelevant? Foreign Policy. December 8, 2010 [Google
   Scholar]
 * 26.This perception has been described by WHO senior leadership in
   conversations with the author.
 * 27.Sridhar D. Who sets the global health research agenda? The challenge of
   multi-bi financing. PLoS Med. 2012;9(9) doi: 10.1371/journal.pmed.1001312.
   [DOI] [PMC free article] [PubMed] [Google Scholar]

--------------------------------------------------------------------------------

Articles from Public Health are provided here courtesy of Elsevier


ACTIONS

 * View on publisher site
 * PDF (305.0 KB)
 * Cite
 * Collections
 * Permalink
   
   
   PERMALINK
   
   Copy


RESOURCES


SIMILAR ARTICLES




CITED BY OTHER ARTICLES




LINKS TO NCBI DATABASES




ON THIS PAGE

 * Abstract
 * Introduction
 * The 1990s: a decade of backsliding in global health
 * 1998–2003: growth and complexity
 * 2003–2012: WHO's diminishing role in global health
 * Conclusion
 * Author statements
 * References


CITE

 * Copy
 * Download .nbib .nbib
 * Format: AMA APA MLA NLM




ADD TO COLLECTIONS

Create a new collection
Add to an existing collection
Name your collection *
Choose a collection
Unable to load your collection due to an error
Please try again
Add Cancel
Follow NCBI
NCBI on X (formerly known as Twitter) NCBI on Facebook NCBI on LinkedIn NCBI on
GitHub NCBI RSS feed

Connect with NLM

NLM on X (formerly known as Twitter) NLM on Facebook NLM on YouTube

National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894

 * Web Policies
 * FOIA
 * HHS Vulnerability Disclosure

 * Help
 * Accessibility
 * Careers

 * NLM
 * NIH
 * HHS
 * USA.gov


Back to Top